Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 13/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205085 | 0.90 | MAPT (0.59) | S1PR4TDP1MAPTHPGDTSHR | |
| SCHEMBL1283086 | 0.89 | MAPT (0.58) | S1PR4TDP1MAPTHPGDTSHR | |
| SCHEMBL11413525 | 0.87 | S1PR4 (0.66) | S1PR4TDP1MAPT | |
| SCHEMBL11840387 | 0.83 | TDP1 (0.56) | S1PR4TDP1MAPTHPGDTSHR | |
| SCHEMBL29559882 | 0.82 | SMN1; SMN2 (0.56) | S1PR4TDP1MAPTHPGDNPC1 | |
| SCHEMBL2000918 | 0.82 | KDM4E (0.54) | S1PR4TDP1MAPTHPGDTSHR | |
| SCHEMBL22866816 | 0.82 | SMN1; SMN2 (0.56) | S1PR4TDP1MAPTHPGDNPC1 | |
| SCHEMBL7237501 | 0.82 | MAPT (0.58) | S1PR4TDP1MAPTHPGDTSHR | |
| SCHEMBL5825119 | 0.82 | S1PR4 (0.56) | S1PR4TDP1MAPTHPGDTSHR | |
| SCHEMBL14861119 | 0.81 | CYP1A2 (0.44) | S1PR4MAPTCYP1A2CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4554356-A | Method for production of imidazolyl vinyl ethers | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1985-11-19 | — | — | US | claimed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| EP-2134685-B1 | 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-8853209-B2 | 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8536195-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| EP-0069754-B1 | METHOD FOR THE PREPARATION OF IMIDAZOLYL-VINYL-ETHERS | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1984-10-10 | — | — | EP | disclosed |
| EP-0119572-A2 | Substituted phenethyl-triazolyl derivatives, process for their preparation and their use as fungicides | BAYER AG (DE) | 1984-09-26 | — | — | EP | disclosed |
| EP-0069754-A1 | METHOD FOR THE PREPARATION OF IMIDAZOLYL-VINYL-ETHERS. | SIEGFRIED AG (CH) | 1983-01-19 | — | — | EP | disclosed |
| EP-0066987-A2 | N-(aryloxyalkyl)-N'-(amino-alkyl) ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-15 | — | — | EP | disclosed |
| WO-1982002552-A1 | METHOD FOR THE PREPARATION OF IMIDAZOLYL-VINYL-ETHERS | ZIRNGIBL LUDWIG | 1982-08-05 | — | — | WO | disclosed |
| EP-0049060-A1 | Imidazoles | BEECHAM GROUP PLC (GB) | 1982-04-07 | — | — | EP | disclosed |
| US-4182776-A | Method of treating lipidemia with aryloxyalkylaminobenzoic acids and esters | AMERICAN CYANAMID COMPANY (US) | 1980-01-08 | — | — | US | disclosed |
| US-4085281-A | ANTIMICROBIALS, HERBICIDES | THE DOW CHEMICAL COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4017631-A | MICROBIOCIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-04-12 | — | — | US | disclosed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | S1PR4 2327/4885TDP1 1161/4885MAPT 4496/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | S1PR4 2327/4885TDP1 1161/4885MAPT 4496/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | S1PR4 2327/4885TDP1 1161/4885MAPT 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.